Tamoxifen and contralateral breast cance
β
Jacek Gronwald; Nadine Tung; William D. Foulkes; Kenneth Offit; Ruth Gershoni; M
π
Article
π
2006
π
John Wiley and Sons
π
French
β 77 KB
## Abstract Women with a mutation in __BRCA1__ or __BRCA2__ face a lifetime risk of breast cancer of βΌ80%, and following the first diagnosis the10βyear risk of contralateral breast cancer is βΌ30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is